SRP033283 Track Settings
 
The RON receptor tyrosine kinase promotes metastasis by triggering epigenetic reprogramming through the thymine glycosylase MBD4 (Bisulfite-Seq) [Breast Cancer Cell Line]   (Human methylome studies)

This track is part of a parent called 'Human methylome studies'. To show other tracks of this parent, go to the Human methylome studies configuration page.

Maximum display mode:       Reset to defaults   

Select views (help):
CpG reads ▾       CpG methylation ▾       AMR       PMD      
Select subtracks by views and experiment:
 All views CpG reads  CpG methylation  AMR  PMD 
experiment
SRX382673 
SRX382674 
SRX382675 
SRX382676 
SRX382677 
SRX382678 
SRX382679 
SRX382680 
SRX382681 
SRX382682 
SRX382683 
SRX382684 
SRX382685 
SRX382686 
SRX382687 
SRX382688 
SRX382689 
SRX382690 
List subtracks: only selected/visible    all    ()
  experiment↓1 views↓2   Track Name↓3  
hide
 SRX382673  CpG methylation  Breast Cancer Cell Line / SRX382673 (CpG methylation)   schema 
hide
 SRX382674  CpG methylation  Breast Cancer Cell Line / SRX382674 (CpG methylation)   schema 
hide
 SRX382675  CpG methylation  Breast Cancer Cell Line / SRX382675 (CpG methylation)   schema 
hide
 SRX382676  CpG methylation  Breast Cancer Cell Line / SRX382676 (CpG methylation)   schema 
hide
 SRX382677  CpG methylation  Breast Cancer Cell Line / SRX382677 (CpG methylation)   schema 
hide
 SRX382678  CpG methylation  Breast Cancer Cell Line / SRX382678 (CpG methylation)   schema 
hide
 SRX382679  CpG methylation  Breast Cancer Cell Line / SRX382679 (CpG methylation)   schema 
hide
 SRX382680  CpG methylation  Breast Cancer Cell Line / SRX382680 (CpG methylation)   schema 
hide
 SRX382681  CpG methylation  Breast Cancer Cell Line / SRX382681 (CpG methylation)   schema 
hide
 SRX382682  CpG methylation  Breast Cancer Cell Line / SRX382682 (CpG methylation)   schema 
hide
 SRX382683  CpG methylation  Breast Cancer Cell Line / SRX382683 (CpG methylation)   schema 
hide
 SRX382684  CpG methylation  Breast Cancer Cell Line / SRX382684 (CpG methylation)   schema 
hide
 SRX382685  CpG methylation  Breast Cancer Cell Line / SRX382685 (CpG methylation)   schema 
hide
 SRX382686  CpG methylation  Breast Cancer Cell Line / SRX382686 (CpG methylation)   schema 
hide
 SRX382687  CpG methylation  Breast Cancer Cell Line / SRX382687 (CpG methylation)   schema 
hide
 SRX382688  CpG methylation  Breast Cancer Cell Line / SRX382688 (CpG methylation)   schema 
hide
 SRX382689  CpG methylation  Breast Cancer Cell Line / SRX382689 (CpG methylation)   schema 
hide
 SRX382690  CpG methylation  Breast Cancer Cell Line / SRX382690 (CpG methylation)   schema 
    

Study title: The RON receptor tyrosine kinase promotes metastasis by triggering epigenetic reprogramming through the thymine glycosylase MBD4 (Bisulfite-Seq)
SRA: SRP033283
GEO: GSE52688
Pubmed: 24388747

Experiment Label Methylation Coverage HMRs HMR size AMRs AMR size PMDs PMD size Conversion Title
SRX382673 Breast Cancer Cell Line 0.609 3.0 62913 9997.8 37 2330.7 1375 702986.6 0.996 GSM1274135: MCF7-RON/MSP_2b; Homo sapiens; Bisulfite-Seq
SRX382674 Breast Cancer Cell Line 0.607 2.4 55580 10511.8 12 1288.2 1237 745819.9 0.995 GSM1274126: MCF7_1a; Homo sapiens; Bisulfite-Seq
SRX382675 Breast Cancer Cell Line 0.607 2.4 54785 10581.6 12 1288.2 1237 745819.9 0.995 GSM1274127: MCF7_1b; Homo sapiens; Bisulfite-Seq
SRX382676 Breast Cancer Cell Line 0.609 2.8 60622 10764.7 19 1093.4 1412 653620.7 0.995 GSM1274128: MCF7_2a; Homo sapiens; Bisulfite-Seq
SRX382677 Breast Cancer Cell Line 0.609 2.8 60622 10764.7 19 1093.4 1412 653620.7 0.995 GSM1274129: MCF7_2b; Homo sapiens; Bisulfite-Seq
SRX382678 Breast Cancer Cell Line 0.608 2.8 59694 10812.0 17 1372.4 1336 690851.4 0.995 GSM1274130: MCF7_3a; Homo sapiens; Bisulfite-Seq
SRX382679 Breast Cancer Cell Line 0.608 2.8 59391 10838.1 17 1372.4 1336 690851.4 0.995 GSM1274131: MCF7_3b; Homo sapiens; Bisulfite-Seq
SRX382680 Breast Cancer Cell Line 0.608 2.5 58063 9649.2 25 1061.8 1295 745395.7 0.996 GSM1274132: MCF7-RON/MSP_1a; Homo sapiens; Bisulfite-Seq
SRX382681 Breast Cancer Cell Line 0.608 2.5 58063 9649.2 25 1061.8 1295 745395.7 0.996 GSM1274133: MCF7-RON/MSP_1b; Homo sapiens; Bisulfite-Seq
SRX382682 Breast Cancer Cell Line 0.609 3.0 62913 9997.8 37 2330.7 1375 702986.6 0.996 GSM1274134: MCF7-RON/MSP_2a; Homo sapiens; Bisulfite-Seq
SRX382683 Breast Cancer Cell Line 0.609 3.0 61485 10046.4 25 1067.1 1389 698205.2 0.996 GSM1274136: MCF7-RON/MSP_3a; Homo sapiens; Bisulfite-Seq
SRX382684 Breast Cancer Cell Line 0.609 3.0 61485 10046.4 25 1067.1 1389 698205.2 0.996 GSM1274137: MCF7-RON/MSP_3b; Homo sapiens; Bisulfite-Seq
SRX382685 Breast Cancer Cell Line 0.580 2.6 56903 13414.7 41 956.0 1367 760138.6 0.996 GSM1274138: MCF7-RON/MSP-shMBD4_1a; Homo sapiens; Bisulfite-Seq
SRX382686 Breast Cancer Cell Line 0.580 2.6 56903 13414.7 41 956.0 1367 760138.6 0.996 GSM1274139: MCF7-RON/MSP-shMBD4_1b; Homo sapiens; Bisulfite-Seq
SRX382687 Breast Cancer Cell Line 0.581 3.0 60150 13541.6 38 1091.5 1477 703896.5 0.996 GSM1274140: MCF7-RON/MSP-shMBD4_2a; Homo sapiens; Bisulfite-Seq
SRX382688 Breast Cancer Cell Line 0.581 3.0 60628 13485.1 38 1091.5 1477 703896.5 0.996 GSM1274141: MCF7-RON/MSP-shMBD4_2b; Homo sapiens; Bisulfite-Seq
SRX382689 Breast Cancer Cell Line 0.581 2.9 59934 13526.1 44 1066.0 1471 706139.4 0.996 GSM1274142: MCF7-RON/MSP-shMBD4_3a; Homo sapiens; Bisulfite-Seq
SRX382690 Breast Cancer Cell Line 0.581 2.9 59356 13595.4 44 1066.0 1471 706139.4 0.996 GSM1274143: MCF7-RON/MSP-shMBD4_3b; Homo sapiens; Bisulfite-Seq

Methods

All analysis was done using a bisulfite sequnecing data analysis pipeline DNMTools developed in the Smith lab at USC.

Mapping reads from bisulfite sequencing: Bisulfite treated reads are mapped to the genomes with the abismal program. Input reads are filtered by their quality, and adapter sequences in the 3' end of reads are trimmed. This is done with cutadapt. Uniquely mapped reads with mismatches/indels below given threshold are retained. For pair-end reads, if the two mates overlap, the overlapping part of the mate with lower quality is discarded. After mapping, we use the format command in dnmtools to merge mates for paired-end reads. We use the dnmtools uniq command to randomly select one from multiple reads mapped exactly to the same location. Without random oligos as UMIs, this is our best indication of PCR duplicates.

Estimating methylation levels: After reads are mapped and filtered, the dnmtools counts command is used to obtain read coverage and estimate methylation levels at individual cytosine sites. We count the number of methylated reads (those containing a C) and the number of unmethylated reads (those containing a T) at each nucleotide in a mapped read that corresponds to a cytosine in the reference genome. The methylation level of that cytosine is estimated as the ratio of methylated to total reads covering that cytosine. For cytosines in the symmetric CpG sequence context, reads from the both strands are collapsed to give a single estimate. Very rarely do the levels differ between strands (typically only if there has been a substitution, as in a somatic mutation), and this approach gives a better estimate.

Bisulfite conversion rate: The bisulfite conversion rate for an experiment is estimated with the dnmtools bsrate command, which computes the fraction of successfully converted nucleotides in reads (those read out as Ts) among all nucleotides in the reads mapped that map over cytosines in the reference genome. This is done either using a spike-in (e.g., lambda), the mitochondrial DNA, or the nuclear genome. In the latter case, only non-CpG sites are used. While this latter approach can be impacted by non-CpG cytosine methylation, in practice it never amounts to much.

Identifying hypomethylated regions (HMRs): In most mammalian cells, the majority of the genome has high methylation, and regions of low methylation are typically the interesting features. (This seems to be true for essentially all healthy differentiated cell types, but not cells of very early embryogenesis, various germ cells and precursors, and placental lineage cells.) These are valleys of low methylation are called hypomethylated regions (HMR) for historical reasons. To identify the HMRs, we use the dnmtools hmr command, which uses a statistical model that accounts for both the methylation level fluctations and the varying amounts of data available at each CpG site.

Partially methylated domains: Partially methylated domains are large genomic regions showing partial methylation observed in immortalized cell lines and cancerous cells. The pmd program is used to identify PMDs.

Allele-specific methylation: Allele-Specific methylated regions refers to regions where the parental allele is differentially methylated compared to the maternal allele. The program allelic is used to compute allele-specific methylation score can be computed for each CpG site by testing the linkage between methylation status of adjacent reads, and the program amrfinder is used to identify regions with allele-specific methylation.

For more detailed description of the methods of each step, please refer to the DNMTools documentation.